Orchard Technologies (OSUR) Q2 2025: Sample Management Down 22% as Consumer Genetics Pause Weighs on Core Growth
Orchard Technologies’ Q2 exposed the drag from a major consumer genetics customer pause, pulling down sample management revenue by 22% even as diagnostics grew and innovation advanced. Despite a challenging funding landscape in public health and research, management maintained discipline, completed a key manufacturing insourcing project ahead of schedule, and launched new products targeting future growth. Investors should watch for the timing of recovery in consumer genomics and the pace of adoption for new proteomics and self-testing platforms into 2026.
Summary
- Consumer Genetics Disruption: Large customer pause drove a sharp sample management decline, muting core revenue momentum.
- Diagnostics Resilience: International and US diagnostics held steady, but public health funding uncertainty clouds near-term demand.
- Innovation Pipeline Focus: New product launches and internal manufacturing set the stage for potential 2026 growth inflection.
Performance Analysis
Orchard Technologies’ Q2 results reflected a bifurcated operating environment, with diagnostics revenue up 3% year over year and sample management solutions (SMS) down 22% due to a single large consumer genetics customer pausing orders. Excluding this customer, SMS would have shown growth, and core revenue would have risen 5%, illustrating underlying demand stability outside this acute headwind. International diagnostics delivered growth despite USAID funding freezes, while US diagnostics slipped just 1% as public health program uncertainty persisted.
Gross margin outperformed expectations, aided by the ahead-of-schedule transition to internal Pennsylvania manufacturing. Operating expenses included one-time items (stock comp, severance, contingent consideration), but the company exited Q2 with a strong cash position and no debt, maintaining flexibility for innovation investments and buybacks. Operating cash flow was negative, as anticipated, given the ongoing Sherlock platform and clinical trial spend.
- Single-Customer Sensitivity: The consumer genetics pause highlighted concentration risk, with $4 million in lost revenue expected for H2 2025.
- Diagnostics Outperformance: Growth in international and clinical settings offset some public health softness, aided by product mix and new partnerships.
- Manufacturing Transition: Internalization of SMS manufacturing drove margin upside and positions OTI for future volume leverage.
Management’s narrative emphasized that, while near-term growth is muted by customer and funding dynamics, foundational investments and product launches are expected to drive a return to growth in 2026.
Executive Commentary
"We reported revenue in Q2 that was in the top half of our guidance range for both total revenue and core revenue. We continue to advance our innovation roadmap in order to expand our portfolio with new products... we substantially completed the transition from external contract manufacturing of our SMS products outside of the U.S. to our internal capabilities in Pennsylvania."
Kerry Eglinton-Manner, President and Chief Executive Officer
"Our gap gross margin in the second quarter was .1% and non-gap gross margin was 43.2%, which was better than our expectations... We expect that our operating efficiencies from the transition to in-house manufacturing will gradually ramp up in the second half of 2025 and gain additional momentum in 2026, which we can optimize further with increasing volume."
Ken McGrath, Chief Financial Officer
Strategic Positioning
1. Customer Concentration and Genomics Volatility
Sample management’s 22% YoY decline was driven by the continued pause from a large consumer genetics customer. Management reiterated that this is not a permanent loss, but a timing issue linked to the customer’s ownership transition. Orders are more likely to resume in 2026, but the episode exposes OTI’s sensitivity to customer concentration in SMS, a segment otherwise positioned for research and clinical growth.
2. Diagnostics Market Diversification
OTI’s diagnostics franchise demonstrated resilience, with steady US revenue and international growth despite funding turbulence. The company is expanding into new clinical settings (ERs, clinics) and leveraging partnerships (e.g., Syphilis Health Check) to offset public health program volatility. The international HIV testing business faces a slower order pace as partners work through inventory, but OTI’s oral fluid-based rapid test remains a differentiator for patient adoption.
3. Innovation Roadmap and New Product Launches
Management highlighted the launch of HemaCollect Protein, a blood collection device targeting proteomics, and progress toward FDA submission for the CALLiP urine collection device. These innovations address high-growth areas in oncology, neurology, and at-home diagnostics, positioning OTI to capture emerging demand for non-invasive, patient-centric testing. Early feedback on HemaCollect was positive, with operational and workflow benefits cited by researchers.
4. Operational Leverage from Manufacturing Insourcing
The completion of SMS manufacturing insourcing months ahead of schedule is a key operational milestone. This shift is expected to drive incremental gross margin improvement as volumes scale, reduce scrap rates, and give OTI more control over cost structure and quality. The benefits will ramp through H2 2025 and into 2026, providing a buffer against external demand shocks.
5. Capital Deployment and Leadership Strengthening
OTI maintained a strong balance sheet, executed $5 million in share repurchases, and continues to evaluate M&A opportunities focused on commercialized innovation. The hiring of a new Chief Commercial Officer with deep diagnostics and life sciences experience underlines a commitment to execution and commercial expansion as new products come to market.
Key Considerations
Q2’s results crystallize both the risks and potential embedded in OTI’s business model, as management juggles near-term headwinds with longer-term growth bets.
Key Considerations:
- Genomics Customer Pause: The timing of recovery for the consumer genetics customer is critical for SMS revenue normalization in 2026.
- Public Health Funding Uncertainty: Federal and international program volatility continues to cloud diagnostics demand visibility.
- Innovation Execution: Success of HemaCollect and CALLiP launches will determine OTI’s ability to offset legacy segment volatility.
- Manufacturing Leverage: Realizing the full benefit of internalized production depends on volume recovery and operational discipline.
- Leadership Transition: The impact of the new Chief Commercial Officer on sales execution and portfolio expansion will be a key watchpoint.
Risks
Ongoing funding uncertainty in public health and research markets remains a material risk, especially for diagnostics volume visibility. The reliance on a small number of large customers in sample management exposes OTI to revenue volatility, as seen this quarter. Execution risk around new product commercialization and the ramp of in-house manufacturing also bears monitoring. Any delays in FDA submissions or muted adoption of new platforms could defer the anticipated 2026 growth recovery.
Forward Outlook
For Q3 2025, Orchard Technologies guided to:
- Revenue of $27 million to $30 million, reflecting lower international HIV orders and Together Take Me Home program timing.
- Gross margin percentage consistent with Q2, as manufacturing efficiencies begin to materialize.
For full-year 2025, management maintained a cautious stance, citing:
- Continued disruption from the consumer genetics customer, with no significant revenue expected from this source in H2.
- Stability in SMS revenue outside the genomics segment, and a slower pace of international HIV orders as inventory is worked down.
Management highlighted several factors that will shape the outlook:
- Potential resumption of Together Take Me Home HIV program funding, but with no clear visibility yet.
- Ramping operational efficiencies from in-house manufacturing, with greater impact expected in 2026 as volumes recover.
Takeaways
Orchard Technologies’ Q2 underscores the company’s exposure to customer and funding volatility, but also its ability to execute on operational improvements and product innovation.
- Core Revenue Sensitivity: A single customer pause in consumer genomics had an outsized impact, revealing the need for further diversification and new segment growth.
- Innovation as a Growth Lever: The launch of HemaCollect Protein and progress on CALLiP and Sherlock platforms are central to OTI’s strategy to offset legacy headwinds and reaccelerate growth by 2026.
- Operational Discipline: Manufacturing insourcing and cost control provide margin stability, but volume recovery and successful commercialization of new products are essential for a sustained turnaround.
Conclusion
Orchard Technologies delivered Q2 results at the high end of guidance despite acute segment headwinds, demonstrating operational agility and a clear focus on innovation. The timing of a genomics rebound and the ramp of new products will determine whether OTI can return to sustainable growth in 2026, as management anticipates.
Industry Read-Through
Orchard’s quarter highlights the ongoing volatility in life sciences tools and diagnostics stemming from funding instability and customer concentration. The pause in consumer genomics demand is a cautionary signal for other suppliers exposed to this segment, while the resilience in diagnostics—especially in differentiated, patient-friendly formats—reinforces the value of product innovation. The success of insourcing manufacturing for margin improvement may inspire similar moves across the sector, especially as companies seek to buffer external shocks and regain control over cost structure. The shift toward at-home and non-invasive testing, as seen with OTI’s pipeline, is likely to remain a durable theme as healthcare delivery evolves.